Merck
1Q Revenues: $10.8 billion, (+8%)
1Q Earnings: $2.9 billion (earnings were $736 million 1Q18)
Comments: Growth in the quarter was driven by Oncology and Vaccines. International sales represented 58% of total sales in the quarter led by China, with $725 million in sales, up 58%. Keytruda sales were up 55% to $2.3 billion. Januvia sales were $1.4 billion, down 5%. Gardasil sales were up 27% to $838 million. Proquad, M-M-R II and Varivax sales were $496 million, up 27%. Bridion sales were up 25% to $255 million. Zetia/Vytorin sales were down 50% to $238 million. Isentress sales were down 9% to $255 million. Simponi sales were down 10% to $208 million.